A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab/relatlimab (Primary) ; Nivolumab/relatlimab (Primary) ; Hyaluronidase
Indications Malignant melanoma
Focus Pharmacokinetics; Registrational
Acronyms RELATIVITY-127
Sponsors Bristol-Myers Squibb

Most Recent Events

04 Mar 2025 Planned End Date changed from 4 Aug 2025 to 18 Nov 2027.
04 Mar 2025 Status changed from recruiting to active, no longer recruiting.
04 Dec 2024 Planned End Date changed from 28 Feb 2025 to 4 Aug 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight